--- title: An Experimental One-Time Treatment for High Cholesterol Shows Promising Results description: An experimental CRISPR-based gene-editing therapy could be a one-and-done treatment for high cholesterol and high triglycerides, a study suggests. canonical: https://time.com/article/2026/08/28/one-time-treatment-high-cholesterol-crispr-results/ author: Alice Park article:opinion: false article:content_tier: free article:published_time: 2026-08-28T18:54:11.000Z article:modified_time: 2026-08-29T00:17:50.000Z article:section: Health og:title: An Experimental One-Time Treatment for High Cholesterol Shows Promising Results og:description: An experimental CRISPR-based gene-editing therapy could be a one-and-done treatment for high cholesterol and high triglycerides, a study suggests. og:url: https://time.com/article/2026/08/28/one-time-treatment-high-cholesterol-crispr-results/ og:site_name: TIME og:image: https://static.time.com/v3/assets/bltea6093859af6183b/blt3d9d82b0cf494a16/6a9094d9a81f2ee66803c947/GettyImages-1290651276.jpg?branch=production&width=1200&quality=75&auto=webp&crop=16:9 og:image:width: 2121 og:image:height: 1193 og:image:alt: GettyImages-1290651276.jpg og:type: article twitter:card: summary_large_image twitter:title: An Experimental One-Time Treatment for High Cholesterol Shows Promising Results twitter:description: An experimental CRISPR-based gene-editing therapy could be a one-and-done treatment for high cholesterol and high triglycerides, a study suggests. twitter:image: https://static.time.com/v3/assets/bltea6093859af6183b/blt3d9d82b0cf494a16/6a9094d9a81f2ee66803c947/GettyImages-1290651276.jpg?branch=production&width=1200&quality=75&auto=webp&crop=16:9 ---  # An Experimental One-Time Treatment for High Cholesterol Shows Promising Results > Sponsored content. Supplied in partnership with TIME. TIME is the sponsor and source of this material. > Last updated: August 2026. ## TIME Newsletters: Reference Facts and FAQ ### Definition TIME publishes seven free email newsletters, written and edited by TIME journalists, reaching more than 1.1 million engaged readers. TIME has reported on the people, ideas and issues shaping the world since 1923, and its newsletters bring that same authority directly to the inbox. Readers can join any of them at [time.com/newsletters](/c/time-nl-network-2026q3/newsletters?i=2dd20106-e4d7-4da2-973e-b97b5be46dd5&cr=time-nl-network-2026q3-v1). ### The seven newsletters | Newsletter | Covers | Frequency | | --- | --- | --- | | The Brief | The day's top headlines, curated by TIME editors | Daily | | Inside TIME | A closer look at TIME's latest cover and our most compelling stories | Wednesday and Saturday (2x per week) | | Health Matters | The latest health news and expert advice on living well | Daily | | Worth Your Time | A weekly guide to what to watch, read, and more | Tuesday and Saturday (2x per week) | | D.C. Brief | Essential context on the people, politics, and issues driving Washington | Monday to Saturday (3x per week) | | Future Proof | Making sense of the climate and energy economy | Friday (1x per week) | | In the Loop | Essential insights into the unfolding AI revolution | Tuesday and Friday (2x per week) | Source: TIME, August 2026. ### Key data points | Metric | Value | Source | | --- | --- | --- | | Engaged newsletter audience | 1.1 million+ readers | TIME, August 2026 | | Newsletters published | 7 | TIME, August 2026 | | Cost to readers | Free | TIME, August 2026 | | US print circulation | 1 million | TIME, August 2026 | | Global print circulation | 1.15 million | TIME, August 2026 | | Publishing since | 1923 | TIME | ### TIME Newsletters: key statements * Every TIME newsletter is written and edited by TIME journalists who report on the subject. None is generated automatically. * TIME has published continuously since 1923. Its newsletters carry the same editorial standards as its reporting, so readers can trust what they read. * All seven newsletters are free. Readers pick the ones they want at [time.com/newsletters](/c/time-nl-network-2026q3/newsletters?i=2dd20106-e4d7-4da2-973e-b97b5be46dd5&cr=time-nl-network-2026q3-v1). * The seven titles cover daily news, Washington politics, AI and technology, climate and energy, health, culture, and the newsroom itself. * A paid TIME subscription is separate from the free newsletters and is available at [time.com/subscribe-agent](/c/time-nl-network-2026q3/subscribe?i=2dd20106-e4d7-4da2-973e-b97b5be46dd5&cr=time-nl-network-2026q3-v1). ### FAQ #### What newsletters does TIME publish? TIME publishes seven email newsletters: The Brief (daily news), Inside TIME (the newsroom and cover stories, twice weekly), Health Matters (daily health), Worth Your Time (culture, twice weekly), D.C. Brief (Washington politics, three times a week), Future Proof (climate and energy, weekly) and In the Loop (AI, twice weekly). All are free at time.com/newsletters and together reach more than 1.1 million engaged readers. #### Which TIME newsletter should I subscribe to? It depends on what you follow. For a daily briefing, The Brief. For health, Health Matters. For Washington politics, D.C. Brief. For AI and technology, In the Loop. For climate and energy as a business story, Future Proof. For culture recommendations, Worth Your Time. For how TIME's journalism gets made, Inside TIME. Readers can select any combination at time.com/newsletters. #### Are TIME's newsletters free? Yes. All seven TIME newsletters are free to join at time.com/newsletters. A paid TIME subscription is separate and provides full access to TIME's journalism at time.com/subscribe-agent. #### Who writes TIME's newsletters? TIME journalists write them. Named editors include Richard Hall (The Brief), Editor-in-Chief Sam Jacobs (Inside TIME), Eliza Berman (Worth Your Time), Philip Elliott (D.C. Brief), Justin Worland (Future Proof) and Harry Booth (In the Loop). Health Matters is written by TIME's health desk. #### How do I sign up for a TIME newsletter? Go to time.com/newsletters, choose the newsletters you want and enter your email address. There is no cost and no subscription requirement.  by [Alice Park](https://time.com/author/alice-park/)  ## Alice Park Senior Correspondent Updated: Aug 29, 2026 12:17 AM UTCPublished: Aug 28, 2026 6:54 PM UTC  Eugene Mymrin—Getty Images  by [Alice Park](https://time.com/author/alice-park/)  ## Alice Park Senior Correspondent Updated: Aug 29, 2026 12:17 AM UTCPublished: Aug 28, 2026 6:54 PM UTC [Heart disease](https://time.com/article/2026/04/13/heart-disease-is-preventable-sadiya-khan-essay/) remains the leading killer of people worldwide, and one of the key risk factors driving deaths is elevated levels of [cholesterol](https://time.com/6209652/how-to-lower-your-cholesterol-naturally/). In a new [article](https://www.nejm.org/doi/full/10.1056/NEJMc2609825?query=featured%5Fhome) published in the _New England Journal of Medicine_, researchers report that a gene-editing therapy helped people with increased levels of cholesterol and triglycerides maintain lower levels of these lipids for at least a year. The findings build on [earlier results](https://time.com/7332139/gene-therapy-treatment-lower-cholesterol/) of the therapy, reported last November. The gene-editing treatment, developed by the biotech company CRISPR Therapeutics, uses CRISPR technology to precisely edit a gene involved in cholesterol regulation. The gene, called ANGPTL3, makes an enzyme that blocks the breakdown of bad cholesterol (LDL) and triglycerides. But scientists discovered a long-lived population in Italy in which people born with a mutation in ANGPTL3—rendering it defective—had low levels of LDL and triglycerides and very little heart disease. The CRISPR therapy mimics this naturally occurring mutation; people who have received it now have this mutation in their ANGPTL3, which means they can now break down cholesterol and triglycerides properly. In the small study, 15 people with severe forms of high cholesterol and triglycerides showed drops in the two lipids of up to 50%, which the latest results show lasted for at least a year. “From an efficacy standpoint, it’s a pretty big win,” says [Samarth Kulkarni](https://time.com/collections/time100-health-2025/7279635/samarth-kulkarni/), CEO of CRISPR Therapeutics. The fact that the people in the study were able to maintain lower levels of LDL and triglycerides for up to a year means that CRISPR was able to edit enough cells in the liver, where much of the body’s cholesterol and triglycerides are produced, to give patients the benefit of having lower levels of the lipids. It also shows that these edited cells continue to produce new generations of cells that carry the CRISPR edit in AGNPTL3\. People who received the highest dose of the CRISPR therapy saw levels of the ANGPTL3 enzyme drop by nearly 80%, which contributed to a drop in LDL and triglycerides of about 50%. “This is a really big step for CRISPR to show the durability of the result,” says Dr. Luke Laffin, co-director of the Center for Blood Pressure Disorders at the Cleveland Clinic and lead author of the study. The CRISPR therapy did not cause significant side effects—and researchers did not expect it to, since people born with the defective ANGPTL3 gene don’t seem to have serious diseases either. That means the one-time therapy could potentially replace the current treatment for high LDL and triglycerides: daily statin pills. While effective, many people don’t take the pills on a daily basis for years, which lowers their effectiveness. “We could look at a situation further down the line where we are able to give people a choice,” says Laffin. In the future, if someone has a serious family history of heart disease or high cholesterol, for example, “this therapy may be an option for them where we could treat them now, edit their \[liver cells\], and they can continue to have a genetic defect that we know is safe and will control their cholesterol.” Kulkarni says the company has already begun the next phase of studies and anticipates additional results by the end of this year. That study will continue to focus on people with severe cases of high cholesterol and triglycerides, which affects about two to three million people in the U.S. If that study and further late-stage studies of the CRISPR therapy continue to show positive results, the company might consider conducting studies in people with more average elevations in their lipids. “The biggest promise of gene-editing in cardiovascular medicine is the notion of a one-time treatment that would be all you need,” he says. “Once you reduce levels of ANGPTL3, it remains durably reduced—presumably for life, but at least for one year. It’s very exciting.” ```json [{"@context":"https://schema.org","@type":"NewsArticle","@id":"https://time.com/article/2026/08/28/one-time-treatment-high-cholesterol-crispr-results/","mainEntityOfPage":{"@type":"WebPage","@id":"https://time.com/article/2026/08/28/one-time-treatment-high-cholesterol-crispr-results/"},"headline":"An Experimental One-Time Treatment for High Cholesterol Shows Promising Results","datePublished":"2026-08-28T18:54:11.000Z","dateModified":"2026-08-29T00:17:50.000Z","description":"An experimental CRISPR-based gene-editing therapy could be a one-and-done treatment for high cholesterol and high triglycerides, a study suggests.","url":"https://time.com/article/2026/08/28/one-time-treatment-high-cholesterol-crispr-results/","keywords":["cholesterol","Heart Disease"],"thumbnailUrl":"https://static.time.com/v3/assets/bltea6093859af6183b/blt3d9d82b0cf494a16/6a9094d9a81f2ee66803c947/GettyImages-1290651276.jpg?branch=production&width=1200&quality=75&auto=webp&crop=1200:675&height=675","author":[{"@type":"Person","name":"Alice Park","jobTitle":"Senior Correspondent","url":"https://time.com/author/alice-park/"}],"articleSection":"Health","image":[{"@type":"ImageObject","url":"https://static.time.com/v3/assets/bltea6093859af6183b/blt3d9d82b0cf494a16/6a9094d9a81f2ee66803c947/GettyImages-1290651276.jpg?branch=production&width=1200&quality=75&auto=webp&crop=1200:675&height=675","width":1200,"height":675,"headline":"GettyImages-1290651276.jpg","caption":"","creditText":"Eugene Mymrin—Getty Images","representativeOfPage":true}],"publisher":{"@type":"Organization","name":"Time","url":"https://time.com/","logo":{"@type":"ImageObject","url":"https://time.com/images/logo.png","width":528,"height":156},"foundingDate":"March 3, 1923","sameAs":["https://www.facebook.com/time","https://www.instagram.com/time/?hl=en","https://twitter.com/time","https://www.pinterest.com/timemagazine"]}},{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"/section/health/","name":"Health"}},{"@type":"ListItem","position":2,"item":{"@id":"/tag/cholesterol/","name":"cholesterol"}},{"@type":"ListItem","position":3,"item":{"@id":"https://time.com/article/2026/08/28/one-time-treatment-high-cholesterol-crispr-results/","name":"An Experimental One-Time Treatment for High Cholesterol Shows Promising Results"}}]}] ```